secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0001651308-23-000134
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene reports H1 2023 R&D expenses of $831M; breakdown by key pipeline assets
-------------------------------------------------------------------------------

- Total R&D expenses for H1 2023 were $831.3M, up from $768.1M in H1 2022.
- Zanubrutinib R&D: $81.1M (H1 2023) vs $71.0M (H1 2022).
- Tislelizumab R&D: $47.0M; Ociperlimab: $38.8M; Pamiparib: $4.4M.
- Bcl-2 (BGB-11417) R&D: $17.5M; OX40 (BGB-A445): $8.9M; other projects: $60.6M.
- Differences between PRC GAAP and US GAAP summarized, mainly share-based comp and leasing treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000134/0001651308-23-000134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000134/bgne-20230829.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer